Australia: The Regulatory and Reimbursement Environment

This article is the third in a three-part series that aims to provide sponsors with information about Australia as a highly attractive option for drug research and development. Australia offers a mature infrastructure and experienced, capable local resources, especially important given global geopolitical uncertainties. Here, we examine the clinical trial start-up processes, regulatory pathway, market access, pricing system, and pricing control, with particular emphasis on cell and gene therapy with a case study to illustrate.

Interested in more? Check out part 1 and part 2.


Open PDF

Return to Insights Center

Related Insights

Article

Lessons from China and the United States on the use of RWE in regulatory submissions

Jul 19, 2021

Article

Near-term strategies for biotech drug developers facing shifting healthcare dynamics

Feb 14, 2024

Video

Part 3: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Video

Part 2: Risk-based Quality Management Video (RBQM) Series

Nov 11, 2021

Article

Decentralized trial tools and technologies are here to stay: A regulatory perspective

Jul 23, 2021

Blog

Ensuring future success in a new market by delivering a robust safety database solution

Aug 4, 2023

Article

Six top tips to prepare for the new EU Clinical Trial Regulation

Apr 13, 2021

Article

Expedited Pathways Comparisons - US EU CHN

Oct 19, 2021

Video

How to transition existing trials under EU-CTR

Feb 1, 2023

Blog

Adoption of the ICH Q12 guideline: New Horizons for Efficient Product Supply Chain Management for a Key Global Market

Nov 13, 2023

Report

New Medicines, Novel Insights: Accelerating development of cell and gene therapies

May 22, 2023

Article

How a joined-up development strategy pays off for early-stage biotechs

May 19, 2021